U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N
Molecular Weight 149.2328
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTERMINE

SMILES

CC(C)(N)CC1=CC=CC=C1

InChI

InChIKey=DHHVAGZRUROJKS-UHFFFAOYSA-N
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C10H15N
Molecular Weight 149.2328
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.31 µM [EC50]
498.0 µM [Ki]
375.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ADIPEX-P

Approved Use

ADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors

Launch Date

-3.47241611E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.78 ng/mL
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
49.1 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2057.33 ng × h/mL
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2000 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.63 h
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Other AEs: Abdominal pain, Dizziness...
Other AEs:
Abdominal pain (6%)
Dizziness (6%)
Early satiety (6%)
Intermittent headache (6%)
Nausea (6%)
Swollen lips (6%)
Upper respiratory infection (6%)
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Other AEs: Anorexia, Back pain...
Other AEs:
Anorexia (6%)
Back pain (6%)
Chapped lips (6%)
Dry skin (6%)
Dyspepsia (6%)
Early satiety (6%)
Irregular pulse (6%)
Nausea (6%)
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Tachycardia, Hypertension...
Other AEs:
Tachycardia
Hypertension
Visual disorders NEC
Nausea
Insomnia
Anxiety
Sources:
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disc. AE: Amnesia, Judgement impaired...
Other AEs: Disorder sleep, Depression...
AEs leading to
discontinuation/dose reduction:
Amnesia (0.3%)
Judgement impaired (0.3%)
Memory impairment (0.3%)
Paraesthesia (0.3%)
Depression (1%)
Anxiety (0.3%)
Vision blurred (0.3%)
Eye pain (0.3%)
Abdominal pain (0.3%)
Tuberculosis skin test positive (0.3%)
Nephrolithiasis (0.3%)
Other AEs:
Disorder sleep (12.9%)
Depression (8.1%)
Anxiety (9.5%)
Cardiac arrhythmia (4.1%)
Ischemic heart disease (1%)
Disturbance in attention (3.1%)
Memory impairment (2%)
Cognitive disorders (1.4%)
Language disorder (0.3%)
Ocular disorders NEC (4.1%)
Dyskinesias and movement disorders NEC (1.4%)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dizziness 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Intermittent headache 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Swollen lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Upper respiratory infection 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Anorexia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Back pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Chapped lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dry skin 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dyspepsia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Irregular pulse 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Anxiety
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Hypertension
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Insomnia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Nausea
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Tachycardia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Visual disorders NEC
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Language disorder 0.3%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Abdominal pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Amnesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Anxiety 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Eye pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Judgement impaired 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Memory impairment 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Nephrolithiasis 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Paraesthesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Tuberculosis skin test positive 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Vision blurred 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Ischemic heart disease 1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Depression 1%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Cognitive disorders 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Dyskinesias and movement disorders NEC 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disorder sleep 12.9%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Memory impairment 2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disturbance in attention 3.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Cardiac arrhythmia 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Ocular disorders NEC 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Depression 8.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Anxiety 9.5%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
weak (co-administration study)
Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively
Page: 39,38
PubMed

PubMed

TitleDatePubMed
Dose effect of fenfluramine-phentermine in the production of valvular heart disease.
1999 Apr
Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota.
1999 Aug 1
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
1999 Jul
Peripheral vasculopathy and nephropathy in association with phentermine.
1999 Jul
Valve replacement for appetite suppressant-induced valvular heart disease.
1999 Jun
Pharmaceutical cost savings of treating obesity with weight loss medications.
1999 Nov
Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters.
1999 Sep
Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy.
1999 Sep
Histologic changes in three explanted native cardiac valves following use of fenfluramines.
1999 Sep-Oct
Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
2000 May
A concise review on the therapeutics of obesity.
2000 Oct
Silver lining to the cloud over anorexogen-related cardiac valvulopathy?
2001 Feb 20
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
2001 Jan
Acyclic neutral carrier-based polymer membrane electrode for a stimulant, phentermine.
2001 Jun
Fluorometric determination of DL-fenfluramine, DL-norfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography.
2001 Nov 5
High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label.
2001 Oct
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis.
2002
Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
2002 Dec 1
Automated headspace solid-phase microextraction and in-matrix derivatization for the determination of amphetamine-related drugs in human urine by gas chromatography-mass spectrometry.
2002 Jan
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.
2002 Jun 7
Phentermine inhibition of recombinant human liver monoamine oxidases A and B.
2002 Mar 1
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion?
2002 Sep-Oct
Noradrenergic modulation of ephedrine-induced hypophagia.
2003 Apr
A comparison of tyrosine against placebo, phentermine, caffeine, and D-amphetamine during sleep deprivation.
2003 Aug
Do these doctors give medicine a black eye?
2003 Dec
Treatment of obesity: an update on anti-obesity medications.
2003 Feb
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
2004 Dec
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY.
2004 Jan
The long-term management of obesity with continuing pharmacotherapy.
2004 Nov
Effects of phentermine and phenformin on biomarkers of aging in rats.
2005 Jan-Feb
Patents

Sample Use Guides

Usual Adult Dose for Weight Loss 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast. Usual Pediatric Dose for Weight Loss 17 years or older: 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration: Oral
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:34:40 UTC 2023
Edited
by admin
on Wed Jul 05 22:34:40 UTC 2023
Record UNII
C045TQL4WP
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PHENTERMINE
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
PHENTERMINE [VANDF]
Common Name English
NSC-759163
Code English
PHENTERMINE [HSDB]
Common Name English
QSIVA
Brand Name English
Phentermine [WHO-DD]
Common Name English
PHENTERMINE [MART.]
Common Name English
BENZENEETHANAMINE, .ALPHA.,.ALPHA.-DIMETHYL-
Systematic Name English
PHENTERMINE [USAN]
Common Name English
DUROMINE
Brand Name English
phentermine [INN]
Common Name English
PHENTERMINE [MI]
Common Name English
α,α-Dimethylphenethylamine
Systematic Name English
PHENTERMINE COMPONENT OF QSYMIA
Brand Name English
QSYMIA COMPONENT PHENTERMINE
Brand Name English
IONAMIN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175651
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
WHO-VATC QA08AA01
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
NDF-RT N0000175423
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
DEA NO. 1640
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
NCI_THESAURUS C29728
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
WHO-ATC A08AA01
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
EMA ASSESSMENT REPORTS QSIVA (REFUSED: OBESITY)
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
LIVERTOX NBK548947
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
NDF-RT N0000175372
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
NDF-RT N0000175372
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
204-522-1
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
INN
1064
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
ChEMBL
CHEMBL1574
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
CHEBI
8080
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
MERCK INDEX
M8644
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY Merck Index
EVMPD
SUB09784MIG
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
HSDB
3158
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
NCI_THESAURUS
C61890
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
NSC
759163
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
WIKIPEDIA
PHENTERMINE
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
DAILYMED
C045TQL4WP
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
PUBCHEM
4771
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
RXCUI
8152
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
FDA UNII
C045TQL4WP
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
SMS_ID
100000082243
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
DRUG BANK
DB00191
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
MESH
D010645
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
CAS
122-09-8
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
IUPHAR
7269
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
DRUG CENTRAL
2140
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023461
Created by admin on Wed Jul 05 22:34:40 UTC 2023 , Edited by admin on Wed Jul 05 22:34:40 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC